Therapeutic approaches for prion and Alzheimer's diseases.

Therapeutic approaches for prion and Alzheimer's diseases. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Therapeutic approaches for prion and Alzheimer's diseases. Abstract Text:

Thomas Wisniewski,Einar M Sigurdsson,

Alzheimer's and prion diseases belong to a category of conformational neurodegenerative disorders [Prusiner SB (2001) N Eng J Med344, 1516-1526; Sadowski M & Wisniewski T (2007) Curr Pharm Des 13, 1943-1954; Beekes M (2007) FEBS J 274, 575]. Treatments capable of arresting or at least effectively modifying the course of disease do not yet exist for either one of these diseases. Alzheimer's disease is the major cause of dementia in the elderly and has become an ever greater problem with the aging of Western societies. Unlike Alzheimer's disease, prion diseases are relatively rare. Each year only approximately 300 people in the USA and approximately 100 people in the UK succumb to various forms of prion diseases [Beekes M (2007) FEBS J 274, 575; Sigurdsson EM & Wisniewski T (2005) Exp Rev Vaccines 4, 607-610]. Nevertheless, these disorders have received great scientific and public interest due to the fact that they can be transmissible among humans and in certain conditions from animals to humans. The emergence of variant Creutzfeld-Jakob disease demonstrated the transmissibility of the bovine spongiform encephalopathy to humans [Beekes M (2007) FEBS J 274, 575]. Therefore, the spread of bovine spongiform encephalopathy across Europe and the recently identified cases in North America have put a large human population at risk of prion infection. It is estimated that at least several thousand Britons are asymptomatic carriers of prion infections and may develop variant Creutzfeld-Jakob disease in the future [Hilton DA (2006) J Pathol 208, 134-141]. This delayed emergence of human cases following the near elimination of bovine spongiform encephalopathy in the UK may occur because prion disease have a very prolonged incubation period, ranging from months to decades, which depends on the amount of inoculum, the route of infection and the genetic predisposition of the infected subject [Hilton DA (2006) J Pathol 208, 134-141]. Therefore, there is a great need for effective therapies for both Alzheimer's disease and prion diseases.

Therapeutic approaches for prion and Alzheimer's diseases. Publishing Authors By Initials

T Wisniewski,EM Sigurdsson,

For similar proteins: prions research abstracts see: proteins: prions research

PUBMED ID PMID:

MEDLINE DATE:

Therapeutic approaches for prion and Alzheimer's diseases. Journal Published:

PUBLICATION TYPE: Review

Journal: The FEBS journal

VOLUME: 274

Page Numbers: 3784-98

Journal Abbreviation: FEBS J.

ISSN: 1742-464X

DAY: 6

MONTH: 07

YEAR: 2007

Therapeutic approaches for prion and Alzheimer's diseases. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101229646

Therapeutic approaches for prion and Alzheimer's diseases. Keywords Mesh Terms:

KEYWORDS: Prions

MESH TERMS: metabolism

Chemical & Substance for Abstract: Therapeutic approaches for prion and Alzheimer's diseases. Information

Substance Name: Prions

Registry Number: 0

Grant and Affiliation Information for Therapeutic approaches for prion and Alzheimer's diseases.

AFFILIATION: Department of Neurology, New York University School of Medicine, NY 10016, USA. thomas.wisniewski@med.nyu.edu

Country: England

AGENCY: United States NIA

GRANT: AG20245

ACRONYM: AG

MEDLINETA: FEBS J

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Therapeutic approaches for prion and Alzheimer's diseases Related Publications

• A nonafluoro nucleoside as a sensitive (19)f NMR probe of nucleic Acid conformation.
• Adenomatosis of sheep's lungs; experimental transmission.
• CT for assessing ventricular remodeling: is it ready for prime time?
• Counterpoint: Sympathetic nerve activity does not influence cerebral blood flow.
• Immunological problems in paratuberculosis.
• Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.
• Lacrimal sac plugging caused by Aspergillus fumigatus.
• Last Word on Point:Counterpoint: Sympathetic nervous activity does/does not influence cerebral blood flow.
• Nanometer distance measurements on RNA using PELDOR.
• Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.
• Rigid spin-labeled nucleoside C: a nonperturbing EPR probe of nucleic acid conformation.
• Session 17. Formation, composition, and detection of habitable extrasolar planets.
• Single base interrogation by a fluorescent nucleotide: each of the four DNA bases identified by fluorescence spectroscopy.
• Site-specific incorporation of nitroxide spin-labels into 2'-positions of nucleic acids.
• The polymorphous light eruption-severity assessment score does not reliably predict the results of phototesting.
• Therapeutic approaches for prion and Alzheimer's diseases.
• Tuberculosis in Iceland: epidemiological studies.
• Vaccination against paratuberculosis (Johne's disease).
• Vasopressin in septic shock: effects on pancreatic, renal, and hepatic blood flow.
• [Experiences from and views on a group practice]
• [The practice guideline 'Acne' (second revision) from the Dutch College of General Practitioners; a response from the perspective of dermatology]